Treatment options and patient perspectives in the management of fibromyalgia: Future trends

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 6, 2008, Pages 1059-1071

  Lawson, Kim ^a  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

Exercise; Fatigue; Fibromyalgia; Pain; Pharmacological treatments; Sleep dysfunction

Indexed keywords

1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIINFLAMMATORY AGENT; BENZODIAZEPINE; CITALOPRAM; DOPAMINE RECEPTOR STIMULATING AGENT; DULOXETINE; FLUOXETINE; GABAPENTIN; GLUTAMIC ACID; HYPNOTIC SEDATIVE AGENT; MILNACIPRAN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE AGONIST; OXYBATE SODIUM; PARACETAMOL; PAROXETINE; PLACEBO; PRAMIPEXOLE; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SUBSTANCE P; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZOLPIDEM; ZOPICLONE;

CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXERCISE; FIBROMYALGIA; HUMAN; INSOMNIA; LOW DRUG DOSE; MONOTHERAPY; NEUROTRANSMITTER RELEASE; NOCICEPTIVE STIMULATION; PAIN ASSESSMENT; PATHOGENESIS; QUALITY OF LIFE; REVIEW; SEDATION; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 60249084829     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s3468     Document Type: Review

References (151)

1. Aaron LA, Bradley LA, Alarcon GS, et al. 1997. Perceived physical and emotional trauma as precipitating events in fibromyalgia: association with health care seeking and disability status but not pain severity. Arthritis Rheum, 40:453-60.
2. Abeles AM, Pillinger MH, Solitar BM, et al. 2007. Narrative review: the pathophysiology of fibromyalgia. Ann Intern Med, 146:726-4.
3. Adiguzel O, Kaptanoglu E, Turgut B, et al. 2004. The possible effect of clinical recovery on regional cerebral blood flow deficits in fibromyalgia: a prospective study with semiquantitative SPECT. South Med J, 97:651-5.
4. Affleck G, Urrows S, Tennen H, et al. 1996. Sequential daily relations of sleep, pain intensity, and attention to pain among women with fibromyalgia. Pain, 68:363-8.
5. Al-Allaf AW, Dunbar KL, Hallum NS, et al. 2002. A case-control study examining the role of physical trauma in the onset of fibromyalgia syndrome. Rheumatol, 41:450-3.
6. Al-Allaf AW, Ottewell L, Pullar T. 2002. The prevalence and significance of positive antinuclear antibodies in patients with fibromyalgia syndrome: 2-4 years' follow-up. Clin Rheumatol, 1:472-7.
7. Anderberg UM, Marteinsdottir I, von Knorring L. 2000. Citalopram in patients with fibromyalgia - a randomized, double-blind, placebo-controlled study. Eur J Pain, 4:27-35.
8. Arendt Neilsen L, Henriksson KG. 2007. Pathophysiological mechanisms in chronic musculoskeletal pain (fibromyalgia): the role of central and peripheral sensitization and pain inhibition. Best Pract Res Clin Rheumatol, 21:465-80.
9. Arnold LM, Goldenberg DL, Stanford SB, et al. 2007a. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum, 56:1336-44.
10. Arnold LM, Hudson EV, Hudson JL, et al. 2002. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med, 112:191-7.
11. Arnold LM, Lu Y, Crofford LJ, et al. 2004. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum, 50:2974-84.
12. Arnold LM, Rosen A, Pritchett YL, et al. 2005. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with FM with or without major depressive disorder. Pain, 119:5-15.
13. Arnold LM, Russell IJ, Duan E, et al. 2007b. A 14-week, randomized, double-blind, placebo-controlled, monotherapy trial of pregabalin (BID) in patients with fibromyalgia syndrome (FMS). Annual Scientific Meeting of American Academy Neurology: www.ampainsoc.org/db2/ abstract/view?poster_id=3119 #695 (accessed 17 May 2008).
14. Arnold LM. 2006. Biology and therapy of fibromyalgia. New therapies in fibromyalgia. Arthritis Res Ther, 8:212.
15. Bäckman E, Bengtsson A, Bengtsson M, et al. 1988. Skeletal muscle functions in primary fibromyalgia: effects of regional sympathetic blockade with guanethidine. Acta Neurol Scand, 77:187-91.
16. Baker K, Barkhuizen A. 2005. Pharmacologic treatment of fibromyalgia. Curr Pain Headache Rep, 9:301-6.
17. Baraniuk JN, Whalen G, Cunningham J, et al. 2004. Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskelet Disord, 5:48.
18. Bartels EM, Danneskiold-Samsøe B. 1988. Histological abnormalities in muscle from patients with certain types of fibrositis. Lancet, 1:755-7.
19. Bengtsson A, Henriksson KG, Larsson J. 1986. Muscle biopsy in primary fibromyalgia. Light-microscopical and histochemical findings. Scand J Rheumatol, 15:1-6.
20. Bennett R, Nelson D. 2006. Cognitive behavioral therapy for fibromyalgia. Nat Clin Pract Rheumatol, 2:416-24.
21. Bennett R. 2005. Fibromyalgia: present to future. Curr Rheum Rep, 7:371-6.
22. Bennett RM, Jones J, Turk DC, et al. 2007. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord, 8:27.
23. Bennett RM, Schein J, Kosinski MR, et al. 2005. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum, 53:519-27.
24. Bennett RM. 1998. Disordered growth hormone secretion in fibromyalgia: a review of recent findings and a hypothesized etiology. Z Rheumatol, 57(Suppl 2):72-6.
25. Bircan C, Karasel SA, Akgün B, et al. 2008. Effects of muscle strengthening versus aerobic exercise program in fibromyalgia. Rheumatol Int, 28:527-32.
26. Bondy B, Spaeth M, Offenbaecher M, et ai. 1999. The T 102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis, 6:433-9.
27. Burckhardt DC, Goldenberg D, Crofford L, et al. 2005. Guideline for the management of fibromyalgia syndrome pain in adults and children. In APS Clinical Pmctice Guidelines Series. No 4. Glenview, IL: American Pain Society.
28. Burkey AR, Carstens E, Jasmin L. 1999. Dopamine reuptake inhibition in the rostral agranular insular cortex produces antinociception. J Neurosci, 19:4169-79.
29. Busch AJ, Schachter CL, Overend TJ, et al. 2008. Exercise for fibromyalgia: a systematic review. J Rheumatol, 35:1130-44.
30. Buskila D, Cohen H, Neumann L, et al. 2004. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry, 9:730-1.
31. Buskila D, Neumann L, Vaisberg G, et al. 1997. Increased rates of fibromyalgia following cervical spine injury: a controlled study of 161 cases of traumatic injury. Arthritis Rheum, 40:446-52
32. Buskila D, Sarzi-Puttini P. 2006. Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome. Arthritis Res Ther, 8:218.
33. Carette S, Bell MJ, Reynolds WJ, et al. 1994. Comparison of amitriptyline, cyclobenzaprine and placebo in the treatment of fibromyalgia. Arthritis Rheum, 37:32-40.
34. Carette S, Oakson G, Guimont C, et al. 1995. Sleep electroencephalography and the clinical-response to amitriptyline in patients with fibromyalgia. Arthritis Rheum, 38:1211-7.
35. Carrillo-de-la-Peña MT, Vallet M, Pérez MI, et al. 2006. Intensity dependence of auditory-evoked cortical potentials in fibromyalgia patients: a test of the generalized hypervigilance hypothesis. J Pain, 7:480-7.
36. Carville SF, Arendt-Nielsen S, Bliddal H, et al. 2008. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis, 67:536-41.
37. Chudler EH, Dong WK. 1995. The role of the basal ganglia in nociception and pain. Pain, 60:3-38.
38. Clark S, Tindall E, Bennett RM. 1985. A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol, 12:980-3.
39. Clark SR, Bennett R. 2000. Supplemental dextromethorphan in the treatment of FM. A double blind, placebo controlled study of efficacy and side effects. Arthritis Rheum, 43:S333.
40. Clauw DJ, Palmer RH, Thacker K, et al. 2007a. Milnacipran efficacy in the treatment of fibromyalgia syndrome: a 15-week randomized, double-blind, placebo-controlled trial. Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting; November 6-11, 2007; Boston, MA. [Abstract #L1].
41. Clauw DJ, Palmer RH, Vitton O, et al. 2007b. The efficacy and safety of milnacipran in the treatment of fibromyalgia. Program and abstracts of the American College of Rheumatology (ACR) 71 st Annual Meeting; November 6-11, 2007; Boston, MA. [Abstract #716].
42. Clauw DJ. 1995. Fibromyalgia: more than just a musculoskeletal disease. Am Fam Physician, 52:853-4.
43. Cohen H, Buskila D, Neumann L, et al. 2002. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis Rheum, 46:845-7.
44. Cohen H, Neumann L, Shore M, et al. 2000. Autonomic dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate variability. Semin Arthritis Rheum, 29:217-27.
45. Cohen SP, Verdolin MH, Chang AS, et al. 2006. The intravenous ketamine test predicts subsequent response to an oral dextromethorphan treatment regimen in fibromyalgia patients. J Pain, 7:391-8.
46. Crofford LJ, Mease PJ, Simpson SL, et al. 2008. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief(FREEDOM): a 6-month double-blind, placebo-controlled trial with pregabalin. Pain, 136:419-31.
47. Crofford LJ, Rowbotham MC, Mease PJ, et al. 2005. Pregabalin for the treatment of fibromyalgia syndrome. Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 52:1264-73.
48. DeMaria S, Hassett AL, Sigal LH, et al. 2007. N-Methyl-D-aspartate receptor-mediated chronic pain: new approaches to fibromyalgia syndrome etiology and therapy. J Musculoskeletal Pain, 15:33-44.
49. Desmeules JA, Cedraschi C, Rapiti E, et al. 2003. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum, 48:1420-9.
50. 2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci, 28:75-82.
51. Drewes AM, Andreasen A, Jennum P, et al. 1991. Zopiclone in the treatment of sleep abnormalities in fibromyalgia. Scand J Rheumatol, 20:288-93.
52. Drexler AR, Mur EJ, Günther VC. 2002. Efficacy of an EMG-biofeedback therapy in fibromyalgia patients. A comparative study of patients with and without abnormality in (MMPI) psychological scales. Clin Exp Rheumatol, 20:677-82.
53. Frink MC, Hennies HH, Englberger W, et al. 1996. Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung, 46:1029-36.
54. Geisser ME, Casey KL, Brucksch CB, et al. 2003. Perception of noxious and innocuous heat stimulation among healthy women and women with fibromyalgia: association with mood, somatic focus, and catastrophizing. Pain, 102:243-50.
55. Geisser ME, Glass JM, Rajcevska LD, et al. 2008. A psychophysical study of auditory and pressure sensitivity in patients with fibromyalgia and healthy controls. J Pain, 9:417-22.
56. Gendreau RM, Thom MD, Gendreau JF, et al. 2005. Efficacy of milnacipran in patients with fibromyalgia. J. Rheumatol, 32:1975-85.
57. Goldenberg DL, Bradley LA, Arnold LM, et al. 2008. Understanding fibromyalgia and its related disorders. Prim Care Companion J Clin Psychiatry, 10:133-44.
58. Goldenberg DL, Clauw DJ, Palmer RH, et al. 2007. One-year durability of response to milnacipran treatment for fibromyalgia. Program and abstracts of the American College of Rheumatology (ACR) 71 st Annual Meeting; November 6-11, 2007; Boston, MA. [Abstract #1526].
59. Goldenberg DL, Felson DT, Dinerman H. 1986. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum, 29:1371-7.
60. Goldenberg DL, Mayskiy M, Mossey C, et al. 1996. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum, 39:1852-9.
61. Goldenberg DL. 2007. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract Res Clin Rheum, 21:499-511.
62. Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, et al. 2000. Ketamine reduces muscle pain, temporal summation and referred pain in fibromyalgia patients. Pain, 85:483-91.
63. Grönblad M, Nykänen J, Konttinen Y, et al. 1993. Effect of zopiclone of sleep quality, moming stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients. A double-blind randomized trial. Clin Rheumatol, 12:186-91.
64. Guedj E, Cammillen S, Colavolpe C, et al. 2007b. Predicative value of brain perfusion SPECT for ketamine response in hyperalgesic fibromyalgia. Eur J Nucl Med Mol Imaging, 34:1274-9.
65. Guedj E, Taieb D, Cammillen S, Lussato D, et al. 2007a. 99mTc-ECD brain perfusion SPECT in hyperalgesic fibromyalgia. Eur J Nucl Med Mol Imaging, 34:130-4.
66. Gur A, Karakoc M, Nas K, et al. 2002. Cytokines and depression in cases with fibromyalgia. J Rheumatol, 29:358-61.
67. Gürsoy S, Erdal E, Herken H. 2003. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int, 23:104-7.
68. Hammond A, Freeman K. 2006. Community patient education and exercise for people with fibromyalgia: a parallel group randomized controlled trial. Clin Rehabil, 20:835-46.
69. Harris RE, Clauw DJ, Scott DJ, et al. 2007. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci, 27:10000-6.
70. Hassett AL, Radvanski DC, Vaschillo EG, et al. 2007. A pilot study of the efficacy of heart rate variability (HRV) biofeedback in patients with fibromyalgia. Appl Psychophysiol Biofeedback, 32:1-10.
71. Hench PK, Cohen R, Mitler MM. 1989. Fibromyalgia: effects of amitriptyline, temazepam and placebo on pain and sleep (abstract). Arthritis Rheum, 32:S47.
72. Henriksson KG. 1999. Is fibromyalgia a distinct clinical entity? Pain mechanisms in fibromyalgia syndrome. A myologist's view. Baillieres Best Pract Res Clin Rheumatol, 13:455-61.
73. Hoffman DL, Dukes EM. 2008. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract, 62:115-26.
74. Holman AJ, Myers RR. 2005. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyaigia receiving concomitant medications. Arthritis Rheum, 52:2495-505.
75. Holman AJ. 2004. Treatment of fibromyalgia with the dopamine agonist ropinirole: a 14-week double-blind, pilot, randomized controlled trial with 14-week blinded extension. Arthritis Rheum, 50:S698.
76. Jain AK, Carruthers BM, van de Sande MI, et al. 2003. Fibromyalgia Syndrome: Canadian clinical working case definition, diagnostic and treatment protocols - a consensus document. J Musculoskeletal Pain, 11:3-107.
77. Jones KD, Adams D, Winters-Stone K, et al. 2006. A comprehensive review of 46 exercise treatment studies in fibromyalgia (1988-2005). Health Qual Life Outcomes. 4:67.
78. Jones KD, Burckhardt CS, Clark SR, et al. 2002. A randomized controlled trial of muscle strengthening versus flexibility training in fibromyaigia. J Rheumatol, 29:1041-8.
79. Jubrias SA, Bennett RM, Klug GA. 1994. Increased incidence of a resonance in the phosphodiester region of 31P nuclear magnetic resonance spectra in the skeletal muscle of fibromyalgia patients. Arthritis Rheum, 37:801-7.
80. Julien N, Goffaux P, Arsenault P, et al. 2005. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain, 114:295-302.
81. Katz RS, Wolfe F, Michaud K. 2006. Fibromyalgia diagnosis: a comparison of clinical, survey, and American College of Rheumatology criteria. Arthritis Rheum, 54:169-76.
82. Kendall SA, Bartels EM, Christensent R. 2004. A meta-analysis of cognitive-behavioural therapy in fibromyalgia. J Musculoskelet Pain, 12(Suppl):49-56.
83. Kosek E, Hansson P. 1997. Modulatory influence on somatosensory perception from variation and heterotropic noxious conditioning stimulation (HNCS) in fibromyaigia patients and healthy subjects. Pain, 70:41-51.
84. Lautenbacher S, Rollman GB. 1997. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain, 13:189-96.
85. Lawson K, Shawcross E, Raphael JH. 2008. Function of potassium channels in blood mononuclear cells of patients with fibromyalgia. J Pain Manage, 1:in press.
86. Lawson K. 2002. Tricyclic antidepressants and fibromyalgia: what is the mechanism of action? Expert Opin Investig Drugs, 11:1437-45.
87. Lawson K. 2006a. Emerging pharmacological therapies for fibromyalgia. Curr Opin Invest Drugs, 7:631-6.
88. Lawson K. 2006b. Potassium channels as targets for the management of pain. CNS Agents in Med Chem, 6:119-28.
89. Lawson K. 2008. Pharmacological treatments of fibromyalgia: do complex conditions need complex therapies? Drug Discov Today, 13:333-40.
90. Lopez-Avila A, Coffeen U, Ortega-Legaspi JM, et al. 2004. Dopamine and NMDA systems modulate long-term nociception in the rat anterior cingulated cortex. Pain, 111:136-43.
91. MacDermott AB, Mayer ML, Westbrook GL, et al. 1986. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurons. Nature, 321:519-22.
92. Maitre M. 1997. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol, 51:337-61.
93. Mannerkorpi K. 2005. Exercise in fibromyalgia. Curr Opin Rheumatol, 17:190-4.
94. Maquet D, Demoulin C, Croisier JL, et al. 2007. Benefits of physical training in fibromyaigia and related syndromes. Ann Readapt Med Phys, 50:363-8.
95. Martinez-Lavin M, Hermosillo AG, Mendoza C, et al. 1997. Orthostatic sympathetic derangement in subjects with fibromyalgia. J Rheumatol, 24:714-8.
96. Martinez-Lavin M, Hermosillo AG, Rosas M, et al. 1998. Circadian studies of autonomic nervous balance in patients with fibromyalgia: a heart rate variability analysis. Arthritis Rheum, 41: 1966-71.
97. Martinez-Lavin M. 2004. Fibromyalgia as a sympathetically maintained pain syndrome. Curr Pain Headache Rep, 8:385-9.
98. Martinez-Lavin M. 2007. Biology and therapy of fibromyalgia. Stress, the stress response system, and fibromyaigia. Arthritis Res Ther, 9:216.
99. Matsutani LA, Marques AP, Ferreira EA, et al. 2007. Effectiveness of muscle stretching exercises with and without laser therapy at tender points for patients with fibromyalgia. Clin Exp Rheumatol, 25:410-5.
100. McIver KL, Evans C, Kraus RM, et al. 2006. NO-mediated alterations in skeletal muscle nutritive blood flow and lactate metabolism in fibromyalgia. Pain, 20:161-9.
101. Mease P, Arnold LM, Bennett R, et al. 2007. Fibromyalgia syndrome J Rheumatol, 34:1415-25.
102. Mease P. 2005. Fibromyalgia Syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheum Suppl, 75:6-21.
103. Mease PJ, Russell IJ, Arnold LM, et al. 2008. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol, 35:502-14.
104. Metyas SK, Arkfeld D, Ibrahim JA, et al. 2007. Inflammatory fibromyalgia: is it real? Ann Rheum Dis, 66(Suppl II):625.
105. Mico JA, Ardid D, Berrocoso E, et al. 2006. Antidepressants and pain. Trends Pharmacol Sci, 27:348-54.
106. Millan MJ. 2002. Descending control of pain. Prog Neurobiol, 66:355-474.
107. Mitler MM, Hayduk R. 2002. Benefits and risks of pharmacotherapy for narcolepsy. Drug Saf, 25:791-809.
108. Moldofsky H, Lue FA, Mously C, et al. 1996. The effect of zolpidem in patients with fibromyalgia: a dose ranging, double-blind, placebo controlled, modified crossover study. J Rheumatol, 23:529-33.
109. Montoya P, Sitges C, García-Herrera M, et al. 2006. Reduced brain habituation to somatosensory stimulation in patients with fibromyalgia. Arthritis Rheum, 54:1995-2003.
110. Nielson WR, Jensen MP. 2004. Relationship between changes in coping and treatment outcome in patients with Fibromyalgia Syndrome. Pain, 109:233-41.
111. Noller V, Sprott H. 2003. Prospective epidemiological observations on the course of the disease in fibromyaigia patients. J Negat Results Biomed, 2:4.
112. Offenbaecher M, Bondy B, de Jonge S, et al. 1999. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum, 42:2482-8.
113. Okumus M, Gokoglu F, Kocaoglu S, et al. 2006. Muscle performance in patients with fibromyalgia. Singapore Med J, 47:752-6.
114. Ozgocmen S, Ozyurt H, Sogut S, et al. 2006. Current concepts in the pathophysiology of FM: the potential role ofoxidative stress and nitric oxide. Rheumatol Int, 26:585-97.
115. Patkar AA, Masand PS, Krulewicz S, et al. 2007. A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med, 120:448-54.
116. Prodinger B, Cieza A, Williams DA, et al. 2008. Measuring health in patients with fibromyalgia: content comparison of questionnaires based on the International Classification of Functioning, Disability and Health. Arthritis Rheum, 59:650-8.
117. Rao SG, Clauw DJ. 2004. The management of fibromyalgia. Drugs Today, 40:539-54.
118. Ressler KJ, Paschall G, Zhou XL, et al. 2002. Regulation of synaptic plasticity genes during consolidation of fear conditioning. J Neurosci, 22:7892-902.
119. Richeimer SH, Bajwa ZH, Kahraman SS, et al. 1997. Utilization patterns of tricyclic antidepressants in a multidisciplinary pain clinic: a survey. Clin J Pain, 13:324-9.
120. Rooks DS, Gautam S, Romeling M, et al. 2007. Group exercise, education, and combination self-management in women with fibromyalgia: a randomized trial Arch Intern Med, 167:2192-200.
121. Rooks DS. 2007. Fibromyalgia treatment update. Curr Opin Rheumatol, 19:111-7.
122. Rossy LA, Buckelew SP, Dorr N, et al. 1999. A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med, 21:180-91.
123. Russell IJ, Bennett RM, Michalek JE, et al. 2005. Sodium oxybate relieves pain and improves sleep in fibromyalgia syndrome [FM]: a randomized, double-blind, placebo-controlled, multi-center clinical trial. Annual Meeting of the American College of Rheumatology. Abst L30.
124. Russell IJ, Mease PJ, Smith TR, et al. 2008. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain, 136:432-44.
125. Russell IJ, Orr MD, Littman B, et al. 1994. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum, 37:1593-601.
126. Salemi S, Rethage J, Wolina U, et al. 2003. Detection of interleukin 1beta (IL-1beta), IL-6 and tumour necrosis factor-alpha in skin in patients with fibromyalgia. J Rheumatol, 30:146-50.
127. Sarzi-Puttini P, Atzeni F, Diana A, et al. 2006. Increased neural sympathetic activation in fibromyalgia syndrome. Ann N Y Acad Sci, 1069:109-17.
128. Schaefer KM. 2003. Sleep disturbances linked to fibromyalgia. Holist Nurs Pract, 17:120-7.
129. Shuto S, Takada H, Mochizuki D, et al. 1995. (+/-)-(Z)-2-(aminomethyl)-1-phenylcyclopropanecarboxamide derivatives as a new prototype of NMDA receptor antagonists. J Med Chem, 38:2964-8.
130. Shyu BC, Kiritsy-Roy JA, Morrow TJ, et al. 1992. Neurophysiological, pharmacological and behavioural evidence for medial thalamic mediation of cocaine-induced dopaminergic analgesia. Brain Res, 572:216-23.
131. Stahl SM, Grady MM, Moret C, et al. 2005. SNRIs: their pharmacology, clinical efficacy and tolerability in comparison with other classes of antidepressants CNS Spectrums, 10:732-47.
132. Staud R, Cannon RC, Mauderli AP, et al. 2003. Temporal summation of pain from mechanical stimulation of muscle tissue in controls and subjects with fibromyalgia syndrome. Pain, 102:87-95.
133. Tanriverdi F, Karaca Z, Unluhizarci K, et al. 2007. The hypothalamicpituitary-adrenal axis in chronic fatigue syndrome and fibromyalgia syndrome. Stress, 10:13-25.
134. Theadom A, Cropley M, Humphrey KL. 2007. Exploring the role of sleep and coping in quality of life in fibromyalgia. J Psychosom Res, 62:145-51.
135. Thieme K, Rose U, Pinkpank T, et al. 2006. Psychophysiological responses in patients with fibromyalgia syndrome. J Psychosom Res, 61:671-9.
136. Thieme K, Turk DC, Flor H. 2007. Responder criteria for operant and cognitive-behavioral treatment of fibromyalgia syndrome. Arthritis Rheum, 57:830-6.
137. Thomas RJ. 1995. Excitatory amino acids in health and disease. J Am Geriatr Soc, 43:1279-89.
138. Turk DC, Dworkin RH. 2004. What should be the core outcomes in chronic pain clinical trials? Arthritis Res Ther, 6:151-4.
139. Turk DC, Flor H. 1989. Primary fibromyalgia is greater than tender points: toward a multiaxial taxonomy. J Rheumatol Suppl, 19:80-6.
140. Turk DC, Okifuji A, Sinclair JD, et al. 1996. Pain, disability, and physical functioning in subgroups of patients with fibromyalgia. J Rheumatol, 23:1255-62.
141. Turk DC, Okifuji A, Sinclair JD, et al. 1998. Interdisciplinary treatment for fibromyalgia syndrome: clinical and statistical significance. Arthritis Care Res, 11:186-95.
142. Vaerøy H, Helle R, Førre O, et al. 1988. Elevated cerebrospinal fluid levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain, 32:21-6.
143. Vitton O, Gendreau M, Gendreau J, et al. 2004. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol, 19:S27-S35.
144. Williams DA, Gracely RH. 2006. Biology and therapy of fibromyalgia. Functional magnetic resonance imaging findings in fibromyalgia. Arthritis Res Ther, 8:224.
145. Wolfe F, Cathey MA, Hawley DJ. 1994. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol, 23:255-9.
146. Wolfe F, Smythe HA, Yunus MB, et al. 1990. The American College of Rheumatology (1990) criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum, 33:160-72.
147. Wolfe F, Zhao S, Lane N. 2000. Preference for non-steroidal anti-inflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum, 43:378-85.
148. Wood PB, Patterson JC 2nd, Sunderland JJ, et al. 2007b. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with PET: a pilot study. J Pain, 8:51-8.
149. Wood PB, Schweinhardt P, Jaeger E, et al. 2007a. Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci, 25:3576-82.
150. Wood PB. 2006. A randomized double-blind, placebo-controlled, parallel-group, multicenter trial comparing the effects of orally administered Xyrem (sodium oxybate) with placebo for the treatment of fibromyalgia. Pain Med, 7:181-2.
151. Yanus MB, Masi AT, Aldag JC. 1989. Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. J Rheumatol, 16:527-32.